Who Owns Syndax Pharmaceuticals Stock?
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 123.47%
- Institutions (% of float)
- 127.09%
- Held by insiders
- 2.85%
- Institutional holders
- 340
- Institutions 97.1%
- Insiders 2.9%
- Public and other 0.0%
Who owns Syndax Pharmaceuticals stock?
Institutional investors own about 123.5% of Syndax Pharmaceuticals's shares, spread across 340 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.85% of SNDX.
The largest institutional holders are Blackrock Inc. (10.30%), Kynam Capital Management, LP (8.94%) and Goldman Sachs Group Inc (6.51%). Together, the top 10 institutions control 53.8% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their SNDX positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of SNDX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 9.27M | 10.30% | +2.8% |
| Kynam Capital Management, LP | 8.05M | 8.94% | 0.0% |
| Goldman Sachs Group Inc | 5.86M | 6.51% | +17.3% |
| State Street Corporation | 4.65M | 5.17% | -17.8% |
| Bank of America Corporation | 4.05M | 4.49% | -4.8% |
| Vanguard Capital Management LLC | 3.95M | 4.39% | +0.7% |
| Deerfield Management Company, L.P | 3.78M | 4.20% | 0.0% |
| Franklin Templeton, Inc. | 3.49M | 3.87% | +52.4% |
| Eversept Partners, LP | 2.80M | 3.11% | -3.0% |
| Hood River Capital Management LLC | 2.56M | 2.85% | +8.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of SNDX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.82M | 3.14% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.55M | 2.83% |
| iShares Trust-iShares Russell 2000 ETF | 2.30M | 2.55% |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.21M | 1.35% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.01M | 1.13% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 973.45K | 1.08% |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 928.02K | 1.03% |
| iShares Trust-iShares Russell 2000 Growth ETF | 831.51K | 0.92% |
| iShares Trust-iShares Biotechnology ETF | 636.92K | 0.71% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 582.82K | 0.65% |
Frequently asked questions
Who is the largest shareholder of Syndax Pharmaceuticals?
Blackrock Inc. is the largest institutional shareholder of SNDX, owning 10.30% of shares outstanding (9.27M shares) as of its latest 13F filing.
What percentage of Syndax Pharmaceuticals is owned by institutions?
Institutions own about 123.5% of SNDX shares and 127.1% of the public float.
How much of Syndax Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 2.85% of SNDX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.